Millennium Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Millennium Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.24M	Buy	+130,000	New	+$1.01M	﹤0.01%	4229
2025 Q3	–	Sell	-100,000	Closed	-$896K	–	6021
2025 Q2	$896K	Buy	+100,000	New	+$931K	﹤0.01%	4492
2024 Q4	–	Sell	-101,300	Closed	-$770K	–	5958
2024 Q3	$770K	Buy	+101,300	New	+$770K	﹤0.01%	4472
2024 Q2	–	Sell	-201,200	Closed	-$1.02M	–	5884
2024 Q1	$1.02M	Sell	201,200 -390,600	-66%	-$2.2M	﹤0.01%	4271
2023 Q4	$3.54M	Buy	591,800 +441,600	+294%	+$2.56M	﹤0.01%	3096
2023 Q3	$1.06M	Buy	150,200 +49,300	+49%	+$354K	﹤0.01%	4146
2023 Q2	$710K	Sell	100,900 -138,400	-58%	-$1.11M	﹤0.01%	4303
2023 Q1	$2M	Buy	239,300 +138,600	+138%	+$1.33M	﹤0.01%	3447
2022 Q4	$1.16M	Buy	+100,700	New	+$1.26M	﹤0.01%	4021
2021 Q2	–	Sell	-40,000	Closed	-$407K	–	6524
2021 Q1	$407K	Buy	+40,000	New	+$412K	﹤0.01%	4995
2020 Q3	–	Sell	-650,000	Closed	-$3.1M	–	4446
2020 Q2	$3.1M	Buy	650,000 +535,900	+470%	+$2.14M	﹤0.01%	2185
2020 Q1	$228K	Buy	114,100 +79,300	+228%	+$218K	﹤0.01%	3320
2019 Q4	$120K	Sell	34,800 -176,200	-84%	-$443K	﹤0.01%	3992
2019 Q3	$604K	Sell	211,000 -589,000	-74%	-$1.83M	﹤0.01%	3133
2019 Q2	$3.03M	Buy	800,000 +400,000	+100%	+$2.41M	﹤0.01%	2138
2019 Q1	$3.26M	Buy	+400,000	New	+$3.42M	﹤0.01%	2062
2017 Q2	–	Sell	-200,000	Closed	-$1.68M	–	3452
2017 Q1	$1.68M	Buy	+200,000	New	+$1.39M	﹤0.01%	2101
2016 Q4	–	Sell	-300,000	Closed	-$1.32M	–	3328
2016 Q3	$1.32M	Buy	+300,000	New	+$1.2M	﹤0.01%	2138

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management's BCRX Position: Q1 2026 in Review

Millennium Management increased its BioCryst Pharmaceuticals (BCRX) stake by 36% in Q1 2026, buying an estimated $389K and bringing the position to 187,721 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3982.

Millennium Management first reported a position in BCRX in Q3 2013 and has held it in 50 quarters since. The position peaked at $37.3M in Q2 2023. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Millennium Management held 187,721 shares of BioCryst Pharmaceuticals worth $1.79M as of Q1 2026.
Millennium Management bought 50,095 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $389K.
BioCryst Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3982 holding.
Millennium Management first reported a position in BioCryst Pharmaceuticals in Q3 2013 and has held it in 50 quarters since.
Millennium Management's BioCryst Pharmaceuticals position peaked at $37.3M in Q2 2023.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.